| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | The 2025 revision of JPOS/JASCC clinical guidelines for delirium in adult patients with cancer: a summary of recommendations. |
| 掲載誌名 | 正式名：Japanese journal of clinical oncology 略 称：Jpn J Clin Oncol ISSNコード：14653621/03682811 |
| 掲載区分 | 国外 |
| 巻・号・頁 | pp.Online ahead of print |
| 著者・共著者 | Yoshinobu Matsuda, Jun Kako, Takaaki Hasegawa, Saho Wada, Hitoshi Tanimukai, Shinichiro Inoue, Kaori Shinsato, Yusuke Kanno, Tetsuro Ishida, Yuichi Kitaura, Akiharu Okamoto, Shuntaro Yasuda, Saki Harashima, Nozomu Oya, Shuji Inada, Yoshinori Saeki, Koji Sugano, Yoshihiro Yamamoto, Masafumi Yoshimura, Takatoshi Hirayama, Tetsuya Ito, Kazuyuki Niki, Yoshiaki Okamoto, Kosuke Yamanaka, Masamitsu Kobayashi, Takafumi Miyoshi, Mari Takeuchi, Ryoichi Sadahiro, Toru Okuyama |
| 発行年月 | 2026/09 |
| 概要 | BACKGROUND:The Japan Psycho-Oncology Society and the Japanese Association of Supportive Care in Cancer revised the clinical practice guidelines for delirium in adult patients with cancer in 2025. In this article, we describe the guideline revision and summarize the updated recommendations.METHODS:These guidelines were developed in accordance with the Minds Manual for Clinical Practice Guideline Development 2020. The multidisciplinary guideline development group formulated four new clinical questions (CQs) addressing delirium prevention (ramelteon and orexin receptor antagonists) and management (combination therapies of antipsychotics with either benzodiazepines or antihistamines). In addition, systematic reviews of 11 existing CQs were updated.RESULTS:Multicomponent interventions were strongly recommended for delirium prevention, based on moderate-certainty evidence. Bright light therapy, antipsychotics, ramelteon, and orexin receptor antagonists were not recommended for prevention. For delirium management, antipsychotics, trazodone, the combination of antipsychotics and benzodiazepines, and opioid switching were suggested, whereas hydroxyzine, benzodiazepines alone, and the combination of antipsychotics and antihistamines were not recommended. All recommendations for delirium management were weak, with low- to very-low-certainty evidence. Background questions addressed delirium assessment tools, precipitating factors, non-pharmacological interventions, and interventions for terminally ill patients.CONCLUSIONS:These revised clinical practice guidelines can serve as a practical framework for optimizing prevention, assessment, and management of delirium in adult patients with cancer in Japan. |
| DOI | 10.1093/jjco/hyag154 |
| PMID | 42766836 |